The MEK1/2 inhibitor U0126 reverses imatinib resistance through down-regulating activation of Lyn/ERK signaling pathway in imatinib–resistant K562R leukemia cells

Author： Shi R.   Lin J.   Guo Y.   Gong Y.P.  

Publisher： Govi-Verlag

ISSN： 0031-7144

Source： Die Pharmazie - An International Journal of Pharmaceutical Sciences, Vol.69, Iss.5, 2014-05, pp. : 346-352

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Related content

Dasatinib a START-R in imatinib-resistant CML

By  

Inpharma, Vol. 1, Iss. 1544, 2006-01 ,pp. : 6-6

Adis International

Access to resources Recommend Favorite

Enhancement of Imatinib-Induced Apoptosis by Matrine in bcr/abl-Positive Leukemia K562 Cells

By Liu Xiao-Shan   Jiang JiKai  

Pharmaceutical Biology (Formerly International Journal of Pharmacognosy), Vol. 44, Iss. 4, 2006-06 ,pp. : 287-291

Informa Healthcare

Access to resources Recommend Favorite

Dasatinib deals to imatinib-resistant disease

By  

Inpharma, Vol. 1, Iss. 1621, 2008-01 ,pp. : 13-14

Adis International

Access to resources Recommend Favorite

Proanthocyanidin from grape seeds enhances doxorubicin-induced antitumor effect and reverses drug resistance in doxorubicin-resistant K562/DOX cells

By Zhang Xiao-Yu   Li Wen-Guang   Wu Yong-Jie   Bai De-Cheng   Liu Nai-Fa  

Canadian Journal of Physiology and Pharmacology, Vol. 83, Iss. 3, 2005-03 ,pp. : 309-318

NRC Research Press

Access to resources Recommend Favorite

Dasatinib: a once-daily option for imatinib-resistant CML

By  

Inpharma, Vol. 1, Iss. 1573, 2007-01 ,pp. : 15-16

Adis International

Access to resources Recommend Favorite